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Abstract 
Phasic myometrial contractility is a key component of human parturition and the contractions 
are driven by reversible phosphorylation of myosin light chains catalyzed by the calcium 
(Ca2+)-dependent enzyme myosin light chain kinase (MYLK). Other yet unknown 
phosphorylation or de-phosphorylation events may contribute to myometrial contraction and 
relaxation. In this study we have performed a global phosphoproteomic analysis of human 
myometrial tissue using tandem mass tagging to detect changes in the phosphorylation status 
of individual myometrial proteins during spontaneous and oxytocin-driven phasic 
contractions.   We were able to detect 22 individual phosphopeptides whose relative ratio 
changed (fold > 2 or < 0.5) in response to spontaneous or oxytocin-stimulated contraction. 
The most significant changes in phosphorylation were to MYLK on serine 1760, a site 
associated with reductions in calmodulin binding and subsequent kinase activity. 
Phosphorylated MYLK (ser1760) increased significantly during spontaneous (9.83 ± 3.27 
fold, P < 0.05) and oxytocin -induced (18.56 ± 8.18 fold, P < 0.01) contractions and we were 
able to validate these data using immunoblotting. Pathway analysis suggested additional 
proteins involved in calcium signalling, cGMP-PRKG signalling, adrenergic signalling and 
oxytocin signalling were also phosphorylated during contractions. This study demonstrates 
that a global phosphoproteomic analysis of myometrial tissue is a sensitive approach to detect 
changes in the phosphorylation of proteins during myometrial contractions, and provides a 
platform for further validation of these changes and for identification of their functional 
significance.  
Key words: Myosin light chain kinase, parturition, phosphoproteomics, myometrium, uterus, 
contractility 
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Introduction 
Human myometrium at parturition contracts in a phasic manner; regular periods of force are 
separated by periods of relaxation. This pattern of contractility is important to allow sufficient 
blood flow through the placenta, providing the fetus with oxygen and removing waste 
products. Myometrial smooth muscle contractility is driven by action potentials which 
provoke rapid entry of calcium into the cell through voltage-gated calcium channels. Force is 
generated after the reversible phosphorylation of myosin light chains (MYL), catalyzed by 
the Ca2+-calmodulin (Ca-CaM)-dependent enzyme myosin light chain kinase (MYLK) [1]. 
Phosphorylation of MYL during myometrial contractions has been demonstrated [1, 2], and 
pharmacological inhibition of MYLK in human myometrium shows that MYLK-induced 
phosphorylation of MYL is essential for force generation [3]. We have previously 
demonstrated that the regulatory subunit of myosin phosphatase (MYPT) can be reversibly 
phosphorylated at an inhibitory site (thr853) during phasic myometrial contractions [2], 
which contributes to oxytocin-induced Ca2+-sensitisation. Others have described changes in 
phosphorylation of HSP27, ERK1/2 and h-caldesmon during myometrial contractions [4, 5]. 
These previous approaches used semi-quantitative mass spectrophotometry (MS) techniques 
and concentrated on a single or a few phosphoproteins at a time, providing valuable but 
limited information.  
 
The purpose of this paper was to carry out a global analysis of the myometrial 
phosphoproteome evoked during spontaneous and oxytocin (OXT)-induced contractions in 
an attempt to discover novel phosphorylation events involved in regulating contractility. We 
have used phospho-peptide enrichment, tandem mass tagging (TMT) and mass spectrometry 
to detect the relative ratio of thousands of phosphopeptides simultaneously. Our approach 
also allowed us to identify peptides which became phosphorylated after OXT signalling.  We 
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have demonstrated robust contraction-induced phosphorylation of MYLK (ser1760) in 
myometrial smooth muscle. Pathway analysis revealed additional proteins involved in 
calcium signalling, cGMP-PRKG signalling, adrenergic signalling and oxytocin signalling 
were also phosphorylated.  
 
Materials and methods. 
Tissue collection. 
This study was approved by the North Somerset and South Bristol Research Ethics 
Committee and all women gave informed written consent. Myometrium was obtained from 
the upper border of the incision in women undergoing elective (not in labour) sections at term 
(37-41 weeks gestation). Indications for caesarean sections included fetal malposition, 
previous section and maternal request. Women with signs of infection were excluded. The 
tissue was washed in ice-cold isotonic saline and transported to the laboratory where it was 
used to prepare tissue strips. 
 
Materials. 
The following chemicals and reagents were obtained from the indicated sources: Oxytocin 
was purchased from Merck (Darmstadt, Germany), and butaprost from Cambridge 
Bioscience (Cambridge, UK). Phospho-MYLK (Ser1760, # 44-1085G) antibody was 
purchased from Invitrogen, Life Technologies (Paisley, UK).  MYLK (# ab76092) antibody 
was purchased from Abcam (Cambridge, UK), and VASP (# 3112) antibody was purchased 
New England Biolabs (Hitchin, UK). All other basic chemicals were supplied by Sigma 
Aldrich (Poole, UK) unless otherwise stated. 
 
Measurement of myometrial contractility. 
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Contractility measurements were carried out using a four chamber Myobath-II system from 
World Precision Instruments (WPI, Stevenage, UK) as previously described [2]. For 
phosphoproteomic studies on relaxed/contracting tissue (Figure 1) spontaneously (SP) 
contracting myometrial strips were treated with or without 10 nM OXT for a period of 
approximately 25 minutes.  Strips were rapidly frozen either 20 sec after the start of a phasic 
contraction (SP-CON or OXT-CON), or following a phasic contraction (relaxed; SP-REL or 
OXT-REL). Tissue was frozen in situ using flat spatulas cooled in liquid nitrogen. The SP-
REL strip was used as a control for subsequent phosphoproteomic analysis and 
immunoblotting quantification. 
 
Tissue homogenisation. 
For phosphoproteomics, frozen tissue strips were homogenised in radioimmunoprecipitation 
assay (RIPA) buffer (50 mM Tris pH 8.0, 150 mM sodium chloride, 1 % NP-40, 0.5 % 
sodium deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), 1x protease (cOmplete) and 
phosphatase (PhosTOP) inhibitor mix (Roche Diagnositics Ltd, Burgess Hill, UK)) at 
approximately 100 mg wet weight/ml using a Polytron homogenizer on ice.  Lysates were 
cleared by centrifugation at 16,000 g for 10 minutes at 4 °C.   Protein concentrations were 
determined using the BCA assay kit (Perbio Science UK, Cramlington, UK) and adjusted to 2 
mg/ml. 100 µg of protein was used for phosphoproteomic analysis as described below. 
 
For SDS-PAGE, frozen tissue strips were homogenised in SDS buffer (25 mM Tris pH 6.8, 2 
% SDS, 10 % glycerol) at approximately 100 mg wet weight/ml using a Polytron 
homogeniser at 20 °C.  Lysates were immediately heated to 95 °C for 5 minutes, and cleared 
by centrifugation at 16,000 g for 10 minutes at 20 °C.   Protein concentrations were 
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determined as above before 12.5 mM dithiothreitol (DTT) and 0.002 % bromophenol blue 
were added prior to electrophoresis. 
 
Phosphoproteomics 
Tandem mass tag (TMT) labelling and phospho-peptide enrichment 
A 100 µg aliquot of each sample (4 conditions per experiment) was digested with trypsin (2.5 
µg trypsin per 100 µg protein; 37 °C, overnight), labelled differentially with TMT four-plex 
reagents according to the manufacturer’s protocol (Thermo Fisher Scientific, Loughborough, 
UK) and the labelled samples pooled. This pool was then subjected to TiO2-based 
phosphopeptide enrichment according to the manufacturer’s instructions (Thermo Fisher 
Scientific).   
Nano-LC mass spectrometry (MS) 
Enriched phosphopeptides were fractionated using an Ultimate 3000 nanoHPLC system in 
line with an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific) as described 
elsewhere [6].  
Data analysis 
The raw data files were processed and quantified using Proteome Discoverer software v1.4 
(Thermo Scientific) and searched against the UniProt Human database using the SEQUEST 
algorithm.  Peptide precursor mass tolerance was set at 10 ppm, and MS/MS tolerance was 
set at 0.6 Da.  Search criteria included oxidation of methionine (+15.9949) and 
phosphorylation of serine, threonine and tyrosine (+79.966) as a variable modifications and 
carbamidomethylation of cysteine (+57.0214) and the addition of the TMT mass tag 
(+229.163) to peptide N-termini and lysine as fixed modifications. Searches were performed 
with full tryptic digestion and a maximum of 1 missed cleavage was allowed.  The reverse 
database search option was enabled and all peptide data was filtered to satisfy false discovery 
7 
 
rate (FDR) of 5%. The TMT tags allowed the abundance of all individual peptides in each of 
the four samples to be reported, and these data were presented as a ratio relative to the SP-
REL sample. Data were then filtered to select only peptides with phosphorylation as a 
modification, and data from four individual experiments were pooled. Statistical analysis was 
carried out using Kruskal-Wallis test and Dunn’s multiple comparison tests for paired 
comparisons relative to SP-REL.  
 
SDS-PAGE, immunoblotting and quantification of immunobands. 
Tissue lysates (50 μg protein) were resolved using 7.5 % Bis-Tris gels and proteins 
transferred by immunoblotting as previously described [7]. Membranes were probed initially 
with phospho-specific antibodies and re-probed with the equivalent total antibody after 
incubating for 3 x 1 hour in stripping buffer (20 mM glycine, 1 % SDS, pH 2).  Bands were 
quantified by densitometry using Quantity One software (Bio-Rad, Hemel Hempstead, UK), 
and care was taken to avoid saturation of signals.  Raw data were normalised to the using an 
experimental control for each experiment as detailed in individual figure legends, and the 
level of phosphorylated MYLK was always normalised using the level of equivalent total 
MYLK.  Data were analysed using Friedman tests and Dunn’s multiple comparison tests 
according to figure legends.  
 
Results 
Analysis of protein phosphorylation during spontaneous and oxytocin-induced myometrial 
contractions. 
OXT (10 nM) stimulation of fresh  myometrial strips resulted in a 212 ± 21.5 % increase in 
contractility relative to the pre-treatment period (as determined by area under curve, AUC) , 
while AUC for spontaneously (SP) contracting strips remained constant throughout the 
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experimental period (102 ± 9.44 % relative to start).  SP or OXT strips were rapidly frozen 
following (relaxed, REL; 3.17 ± 0.35 min post peak) or during (contracting, CON; after 20 
sec) a phasic contraction (Figure 1). The mean time taken for contractions to reach their peak 
was 34.5 ± 2.39 seconds. This provided us with four experimental groups; SP-REL, SP-CON, 
OXT-REL and OXT-CON. Lysates from frozen tissue samples were used for phospho-
proteomic analysis, and over 4000 phosphopeptides were identified in our samples. Table 1 
summarizes the identities of 22 phosphopeptides whose relative ratio changed (either fold >2 
or fold < 0.5) in response to spontaneous or OXT- stimulated contraction, or in response to 
OXT exposure (effect of OXT in the relaxed state). There were significant changes in MYLK 
(ser1760, P < 0.001), CAMK2G (ser325, P < 0.01), dematin (DMTN, ser226, P < 0.05) and 
serine/arginine repetitive matrix protein 1 (SRRM1, ser696, P < 0.05) phosphorylation which 
all increased during a spontaneous contraction. MYLK (ser1760), CAMK2G (ser325) and 
SRRM1 (ser696) increased with OXT stimulation as well as contraction, while calcium-
transporting ATPase (ATP2B4, ser1136), tensin-1 (TNS1, ser445), myosin phosphatase 
regulatory subunit 12B (PPP1R12B, ser839 and ser947), synaptopodin-2 (SYNPO2, 
thr588/ser604), Kininogen-1 (KNG1, ser332) and KN motif and ankyrin repeat domain-
containing protein 2 (KANK2, ser356) all increased with OXT exposure but not contraction. 
MYLK at an alternative site (ser1772/3/6), ELKS/Rab6-interacting/CAST family member 1 
(ERC1, ser21), microtubule-associated protein 1B (MAP1B, ser2200/2), CLIP-associating 
protein 2 (CLASP2, ser455) and synemin (SYMN, ser1044) decreased in phosphorylation 
during a spontaneous contraction (all P < 0.05). The same proteins, in addition to neuroblast 
differentiation-associated protein (AHNAK, ser3426) and leiomodin-1 (LMOD1, ser555 and 
ser508/512/516) decreased in phosphorylation with OXT stimulation. The potential 
associations between phosphorylated proteins were determined by pathway analysis which 
placed MYLK phosphorylation central to myometrial contractility (Figure 2). The analysis 
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revealed statistically significant protein-protein interaction enrichment (P = 3.46e-08) 
suggesting these proteins may interact in vivo. 
 
Confirmation of MYLK phosphorylation during phasic contractions. 
The tension generated by spontaneous and oxytocin-augmented contractions is shown in 
Figure 3A. The phospho-proteomic data demonstrate that phosphorylated MYLK (ser1760) 
increases significantly during spontaneous (9.83 ± 3.27 fold, P < 0.05) and OXT-induced 
(18.56 ± 8.18 fold, P < 0.01) contractions, with modest increases in relaxed tissues after OXT 
exposure which failed to reach significance (2.24 ± 0.60 fold, Figure 3B). The level of 
pMYLK (ser1760) in these samples was confirmed by western blotting (Figure 3D and E), 
and the pattern of phosphorylation was closely coupled to the level of tension in the 
myometrial strips at the point of freezing (Figure 3A). Interestingly phosphorylation of 
MYLK at serine 1772/3/6 was markedly decreased with spontaneous contractions (0.45 ± 
0.18 fold) and similarly after OXT stimulation, in relaxed and contracted tissue (0.40 ± 0.18 
and 0.44 ± 0.15 fold respectively, Figure 3C). These data demonstrate that serine 1760 and 
serines 1772/3/6 on MYLK are phosphorylated at the peak and trough of a phasic contraction 
respectively and suggest that separate signalling pathways and protein kinases are 
responsible. 
 
MYLK is not phosphorylated during butaprost-induced relaxation. 
We next investigated whether PKA-activating receptors caused phosphorylation of serine 
1760 of MYLK in intact myometrium. This is important because MYLK is a proposed target 
of PKA-dependent myometrial relaxation on the basis that it is phosphorylated by PKA in 
vitro [8], and pMYLK (ser1760) has decreased myosin kinase activity [9, 10].  The EP2-
receptor agonist, butaprost, causes cAMP elevation in human myometrial cells [11]. 
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Phosphorylation of MYLK was measured in butaprost-relaxed tissue (10-6 M dose) and 
compared to the SP-REL and SP-CON levels in matched strips (Figure 4A). While 
contraction was associated with increased pMYLK (ser1760), there was no increase in the 
butaprost-treated strips (Figure 4B, C and D), despite increased phosphorylation of the PKA 
substrate VASP at serine 157. Moreover, the level of pMYLK was closely coupled to the 
level of tension at freezing (Figure 4B).  
 
Discussion 
This paper reports a phosphoproteomic approach to study the mechanism of contractility in 
human myometrium.  We have carried out a global phosphorylation analysis of relaxed 
versus contracted myometrial tissue using advanced quantitative proteomic techniques. This 
approach has highlighted the importance of MYLK phosphorylation and revealed several 
proteins possibly associated with MYLK whose phosphorylation also changes during 
contractions. We have verified the phosphorylation of MYLK by western blotting, 
demonstrated that serine 1760 phosphorylation is closely coupled to the generation of force, 
and that it does not increase during butaprost-induced myometrial relaxation.  
 
The phasic nature of myometrial contraction and relaxation is driven through the reversible 
phosphorylation of MYL, catalyzed by MYLK. The essential need for MYLK-mediated 
phosphorylation of MYL has been demonstrated in human myometrium [3], although MYL 
phosphorylation-independent pathways may be complementary in other species [12]. Our 
study has revealed phasic changes in the phosphorylation of 18 proteins (4 with multiple 
phosphorylation sites), with the greatest change in phosphorylation on serine 1760 of MYLK. 
Pathway analysis of these proteins revealed components of the calcium signalling pathway 
(KEGG 04020), the cGMP-PRKG signalling pathway (KEGG 04022), adrenergic signalling 
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in cardiomyocytes (KEGG 04261) and the oxytocin signalling pathway (KEGG 04921), and 
suggested these proteins may interact in vivo. These proteins are likely to be functionally 
relevant and their involvement in uterine contractions requires further investigation. More 
specifically, LMOD1 and CAMK2G are involved in the maintenance of a contractile 
phenotype in vascular smooth muscle cells [13, 14] but their role in myometrial smooth 
muscle has not been investigated. The myosin phosphatase regulatory subunit family of 
proteins (PPP1R12A, B and C) is well conserved [15] and is involved in calcium 
sensitization mechanisms in human myometrium [16]. AHNAK binds to and stimulates L-
type Ca2+channel activity and can be regulated by PKA-mediated phosphorylation [17], and 
provides a link between Ca2+channels and the actin cytoskeleton [18]. Phospholamban (PLN) 
is a negative regulator of calcium ion import into the sarcoplasmic reticulum and its role in 
regulating the frequency and amplitude of contractions in rat myometrium has been described 
[19] but there is little information on the function of this protein in human uterine activity. 
ATP2B4 (or PMCA) is part of the Ca2+ extrusion mechanism responsible for lowering [Ca2+]i 
and force after stimulation [20].  KNG1 is cleaved to release bradykinin, which is able to 
stimulate myometrial contractility [21] by stimulating IP3-dependent Ca
2+ release and the 
bradykinin B2 receptor is expressed in the myometrium at term [22]. Interestingly, the 
phosphorylation of KANK2 (SRC-1-interacting protein, SIP) by epidermal growth factor has 
recently been described in human myometrial cells [23]. Phosphorylated KANK2 is a 
potential mediator of human parturition through stimulation of prostaglandin synthesis [23].  
The discovery of multiple accessory proteins whose activity is regulated during contractions 
represents potential new targets for modulating uterine activity at labour. 
 
It is well established that MYLK activity can be regulated by phosphorylation in addition to 
its regulation by Ca-CaM. Early studies in tracheal smooth muscle established that 
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phosphorylation of MYLK at serine 1760 (peptide A) in the calmodulin binding domain 
interferes with CaM binding and increases Kcam, thereby decreasing kinase activity [9, 10]. 
Phosphorylation of MYLK at serine 1773 (peptide B) can occur irrespective of CaM binding 
and both these sites can be phosphorylated in vitro by cAMP-dependent protein kinase (PKA) 
[8] and calmodulin-dependent kinase II (CAMK2) [24]. Studies in myometrial smooth 
muscle have demonstrated CAMK2-dependent decreases in MYLK activity during a phasic 
contraction, however phosphorylation of MYLK was not measured [1]. Our observation that 
MYLK phosphorylation (ser1760) increases during a contraction, shown by 
phosphoproteomics and verified by western blotting, supports these previous findings and 
suggest that CAMK2-dependent phosphorylation of MYLK may negatively regulate MYLK 
activity at high [Ca2+]i [25]. Activation of the prostaglandin receptor EP2 subtype with 
butaprost results in cAMP elevation in human myometrium [11, 26]. While butaprost 
treatment resulted in increased PKA activity as determined by the level of VASP 
phosphorylation, there was no increase in pMYLK (Ser1760) in butaprost-relaxed tissue. 
This suggests that phosphorylation of serine 1760 is not a mechanism for agonist-induced 
myometrial relaxation [27, 28]. It is possible that PKA-dependent uterine relaxation is 
mediated by other pathways, e.g. activation of potassium channels in myometrial cells [27, 
29]. 
 
In conclusion we have developed a sensitive method for the quantitative analysis of multiple 
protein phosphorylation events in human myometrial tissue and have confirmed the central 
role of MYLK phosphorylation during spontaneous and OXT-enhanced contractions. The 
functional role of additional proteins listed in Table 1 and the protein kinases/phosphatases 
involved in their regulation requires further investigation. This paper will stimulate the study 
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of novel protein targets in the control of uterine contractility to prevent preterm labour or to 
facilitate induction of labour. 
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Figure legends 
 
Figure 1. Spontaneous and oxytocin-induced phasic contractions – experimental design for 
phosphoproteomic study. 
Spontaneously contracting myometrial strips (SP) were treated with or without 10 nM 
oxytocin (OXT). Strips were rapidly frozen after 26.3 ± 2.88 min either 20 sec after the start 
of a phasic contraction (CON), or immediately following a phasic contraction (REL, 3.17 ± 
0.35 min post peak), depicted by open circles. Tissue lysates were subsequently used for 
phospho-proteomic studies.  
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Figure 2. STRING diagram summarising phosphoproteomic data.  
The potential associations between proteins phosphorylated during spontaneous and OXT-
induced contractions are shown. Stronger associations are represented by thicker lines. This 
group of proteins show a statistically significant protein-protein interaction enrichment (P = 
3.46e-08), suggesting these proteins may interact in vivo. 
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Figure 3. Confirmation of MYLK phosphorylation during phasic contractions by western 
blotting. 
A, myometrial tension (g) at the point of freezing as depicted in Figure 1. Phosphoproteomic 
data for pMYLK (ser1760) (B) and pMYLK (ser1772/3/6) (C) expressed as fold change 
relative to SPONT-REL. Proteins lysates were also resolved by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). The levels of pMYLK (ser1760) and 
MYLK were determined by western blotting (D), and quantified by densitometry; pMYLK 
data were normalised to MYLK levels and expressed as fold change relative to SPONT-REL 
(E). Data were analysed using Friedman tests (P value indicated) and Dunn's multiple 
comparisons tests; *, P < 0.05l; **, P < 0.01 and ***, P < 0.001 for comparison to SPONT-
REL, n=4. 
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Figure 4. MYLK is not phosphorylated during butaprost-induced relaxation. 
A, spontaneously contracting myometrial strips were treated with or without 1 µM butaprost 
(BUTA) as indicated. Non-treated strips were frozen either 20 sec after the start of a phasic 
contraction (CON), or immediately following a phasic contraction (REL), and BUTA strips 
were frozen 20 min after butaprost addition, depicted by open circles. B, myometrial tension 
(g) at the point of freezing. C, tissues were homogenized and proteins resolved by SDS-
PAGE; phosphorylated MYLK (ser1760), MYLK and VASP were detected by western 
blotting. Phosphorylated VASP (ser157) is seen as a slower migrating band. D, pMYLK 
(ser1760) levels were quantified by densitometry and data were normalised to the level of 
MYLK. Statistical significance of tension and phosphorylation data were determined by 
Friedman tests and Dunn’s multiple comparison tests; * P < 0.05, n=4. 
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Table 1. 
                   Phosphoproteomic analysis of relaxed and contracting human myometrial tissue<comma> with and without oxytocin stimulation. 
Description Gene Accession Sequence Site (s) 
SP-
CON 
OXT-
REL 
OXT-
CON P 
   
Mean ratio SEM 
Mean 
ratio SEM Mean ratio SEM 
      Myosin light chain kinase MYLK Q15746 LSsMAMISGLSGR S1760 9.83* 3.27 2.24 0.6 18.56** 8.18 0.0001c 
Calcium/calmodulin-dependent protein kinase II 
gamma CAMK2G Q13555 QSSAPAsPAASAAGLAGQAAK S325 3.77 1.74 2.63 1.16 3.10* 1.52 0.010 b 
Alpha-2-HS-glycoprotein AHSG P02765 CDSSPDsAEDVR S138 2.67 0.96 1.49 0.27 2.25 0.78 0.073 
Dematin DMTN Q08495 RGAEEEEEEEDDDsGEEMK S226 2.43 1.16 1.19 0.19 2.67* 0.87 0.034a 
Serine/arginine repetitive matrix protein 1 SRRM1 Q8IYB3 APQTSSsPPPVR S696 2.35 0.68 2.57 0.58 3.10* 0.98 0.017a 
KNG1 protein KNG1 P01042 ETTCSKEsNEELTESCETK S332 2.32 0.73 1.7 0.2 2.82* 0.66 0.053 
Cardiac phospholamban PLN P26678 RAsTIEMPQQAR S16 2.14 0.4 2.13 0.63 2.14 0.18 0.088 
ELKS/Rab6-interacting/CAST family member 1 ERC1 Q8IUD2 VEPSSQSPGRsPR S21 0.48 0.09 0.34 0.1 0.4 0.01 0.047a 
Microtubule-associated protein 1B MAP1B P15205 HMDPPPAPVQDRsPsPR S2200<comma> S2202 0.47 0.12 0.33* 0.08 0.38 0.09 0.016a 
Myosin light chain kinase MYLK Q15746 ssTGsPTSPLNAEK 
S1772<comma> S1773<comma> 
S1776 0.45 0.18 0.40* 0.18 0.44 0.15 0.019a 
Synemin SYNM O15061 QRsPAPGSPDEEGGAEAPAAGIR S1044 0.42 0.09 0.40* 0.12 0.46 0.1 0.017a 
CLIP-associating protein 2 CLASP2 O75122 VVSQsQPGsR S455 0.41 0.09 0.42 0.16 0.57 0.08 0.045a 
Calcium-transporting ATPase ATP2B4 P23634 LVPsSSYVAVAPVK S1136 0.7 0.04 6.94 2.72 9.1 6.24 0.0002c 
Tensin-1 TNS1 Q9HBL0 LLsGFGLER S445 1.23 0.15 6.55 1 7.59 1.67 0.010 b 
Myosin phosphatase regulatory subunit 12B PPP1R12B O60237 LEsGGSNPTTSDSYGDR S839 0.94 0.26 5.21 0.91 5.32 1.68 0.001c 
Synaptopodin-2 SYNPO2 Q9UMS6 tAKPFPGSVNQPATPFsPTR T588<comma> S604 1.78 0.36 4.14* 2.05 3.55* 1.02 0.007 b 
KN motif and ankyrin repeat domain-containing 
protein 2 KANK2 Q63ZY3 AQsLEPYGTGLR S356 1.05 0.06 1.99 0.31 2.12 0.19 0.010 b 
Myosin phosphatase regulatory subunit 12B PPP1R12B O60237 KMsEMEEEMK S947 1.09 0.23 1.79 0.25 2.26* 0.21 0.010 b 
Neuroblast differentiation-associated protein AHNAK Q09666 VSMPDVELNLKsPK S3426 0.56 0.08 1.29 0.22 0.47* 0.09 0.001c 
Calcium/calmodulin-dependent protein kinase II 
gamma CAMK2G Q5SWX3 QEtVECLR T287 0.53 0.14 0.40* 0.05 0.71 0.18 0.031a 
Leiomodin-1 LMOD1 P29536 NSLsPATQR S555 0.86 0.4 0.35* 0.14 0.36 0.09 0.032a 
Leiomodin-1 LMOD1 P29536 GsPKPsPQPsPKPSPK 
S508<comma> S512<comma> 
S516 0.63 0.34 0.20* 0.06 0.21 0.06 0.016a 
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